Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ascletis

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

- PMLiVE

GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

GSK will evaluate the therapy in combination with its own hepatitis B treatment

- PMLiVE

MIT study reveals why certain immunotherapies do not always work

The findings could help doctors determine which drugs would benefit patients most

- PMLiVE

US study finds potential new way of improving immunotherapy for tumours

‘Warming up’ cold tumours assisted immunotherapy in tackling tumours

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

Gilead’s Vemlidy gets FDA approval for paediatric patients with chronic hepatitis B infection

The application was supported by positive 24-week data from a phase 2 trial

- PMLiVE

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

Say Communications

- PMLiVE

Gilead announces positive Biktarvy data for HIV and hepatitis B

The results were presented at the 24th International AIDS Conference

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

AbbVie signs immunotherapy pact with I-Mab worth $2bn

Focus of deal is anti-CD47 monoclonal antibody lemzoparlimab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links